NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyQuick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)
About This Grant
-Purpose. This FOA is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application. -Mechanism of Support. This FOA will use the NIH exploratory/developmental (R21) grant mechanism for exploratory, pilot projects. Applicants planning to propose fully developed research projects supported by preliminary data should consider a related FOA (PA-07-356) that solicits applications for clinical therapeutic and preventive trials under the NIH research project (R01) grant mechanism. -Funds Available and Anticipated number of Awards: Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known.
Grant Summary
Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21) is a National Institutes of Health grant providing up to $250K for municipality. Applications are accepted on a rolling basis. Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
Requirements
- Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application
- peer review
How to Apply
Up to $250K
Rolling / Open
- 1Confirm your organization is eligible for Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21): Frequently Asked Questions
Who is eligible for the Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)?
Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21) is offered by National Institutes of Health and is generally open to municipality. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21) provide?
Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21) provides up to $250K per award from National Institutes of Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21) deadline?
Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21) accepts applications on a rolling or ongoing basis, so there is no single fixed deadline. Confirm current timing with the funder, National Institutes of Health, before you apply, and submit as early as possible because rolling programs can close once funds are committed.
How do you apply for the Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)?
To apply for Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.